Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000879169-25-000035
Filing Date
2025-01-22
Accepted
2025-01-22 16:07:22
Documents
3
Period of Report
2025-01-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1737580032.html 4  
1 FORM 4 wk-form4_1737580032.xml 4 3900
2 EX-24 cagnoni-incytesection16p.htm EX-24 3648
3 cagnoni-incytesection16p001.jpg GRAPHIC 246407
  Complete submission text file 0000879169-25-000035.txt   348794
Mailing Address 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Business Address 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 3024986700
INCYTE CORP (Issuer) CIK: 0000879169 (see all company filings)

EIN.: 943136539 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)

Mailing Address ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080
Business Address
CAGNONI PABLO J (Reporting) CIK: 0001205703 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-12400 | Film No.: 25545994